CardioNerds Drs. Jason Feinman, Gurleen Kaur, and Rick Ferraro discuss the implementation of SGLT inhibitors in clinical practice with Dr. Alison Bailey. Notes were drafted by Dr. Jason Feinman.
In this episode, we discuss the implementation of SGLTi in clinical practice scenarios, including for individuals with heart failure regardless of ejection fracti ... Show More
Nov 7
434. Heart Failure: Advanced Therapies Evaluation with Dr. Michelle Kittleson
CardioNerds kicks off its advanced therapies series with Chair of the CardioNerds Heart Failure Council, Dr. Jenna Skowronski, co-chair of the series, Dr. Shazli Khan, and Episode FIT lead, Dr. Jason Feinman. In this first episode, they discuss the process of advanced therapies e ... Show More
14m 1s
Nov 5
433. The Evolution and Future of Cardio-Obstetrics with Dr. Afshan Hameed, Dr. Doreen DeFaria Yeh, Dr. Garima Sharma, and Dr. Rina Mauricio
In this second episode of a collaborative series with the AHA Women in Cardiology (WIC) Committee, CardioNerds (Dr. Gurleen Kaur and Dr. Anna Radhakrishnan) are joined by four leading experts in Cardio-Obstetrics to explore this rapidly evolving field. Dr. Rina Mauricio (Director ... Show More
31m 35s
Jun 2025
Dapagliflozin in Patients Undergoing Transcatheter Aortic Valve Implantation
The DapaTAVI trial, conducted across 39 centers in Spain, is the first study to evaluate the use of sodium-glucose co-transporter-2 (SGLT-2) inhibitors, specifically dapagliflozin, in patients with heart failure undergoing transcatheter aortic valve implantation (TAVI). The trial ... Show More
9m 4s
Jan 2025
Review of the Primary Angioplasty in Myocardial Infarction Study Group trial
N Engl J Med 1993;328:673-679Background: Previous trials established that thrombolysis improves mortality in patients with acute myocardial infarction, as seen in the GISSI-1 and ISIS-2 trials. However, thrombolysis has limitations, including an increased risk of bleeding and the ... Show More
12m 26s
Sep 12
Sep 12 2025 This Week in Cardiology
More from ESC including: Valvular HD guidelines, a new drug class for HTN, myosin inhibition in HCM, vericiguat, and digoxin are the topic discussed by John Mandrola, MD. This podcast is intended for healthcare professionals only. To read a partial transcript or to comment, visit ... Show More
31m 5s
Nov 2020
Covid-19 and comorbidities
A recent meta-analysis by Espinosa and colleagues, “Prevalence of Comorbidities in Patients and Mortality Cases Affected by SARS-CoV2”, found that 42% of patients with Covid-19 had comorbidities. Furthermore, 61% of those with Covid-19 admitted to the Intensive Care Unit had como ... Show More
14m 43s
Sep 8
Reframing Cardiovascular Care | JACC This Week
In this episode, Dr. Harlan Krumholz introduces the September 16, 2025 issue of JACC, which features studies that challenge conventional clinical thinking, including a detailed ECMO physiology study showing that higher ECMO flow does not uniformly raise pulmonary capillary wedge ... Show More
13m 24s
Sep 15
AI, Polygenic Risk Scores, and Antithrombotic Therapy | JACC This Week
In this episode, Editor-in-Chief Harlan Krumholz explores the evolving landscape of cardiovascular medicine, beginning with a call for responsible stewardship of artificial intelligence. Highlights include a major registry study on percutaneous aspiration for right-sided endocard ... Show More
9m 54s
Apr 2023
Dr Joseph Radich | How to Fix a Broken Sick Care System, Cutting Edge Health Bio-Hacks, Reducing High Blood Pressure & More! KKP: 573
Today, I am blessed to have Dr Joseph Radich. Dr Radich founded R3 Health, a safe and trustworthy VIP experience designed to solve its members' health, medical, and lifestyle problems. They believe that individualized healthcare is the key to achieving optimal and balanced wellne ... Show More
58m 40s